INTRODUCTION

11
C-Pittsburgh compound B ( 11 C-PIB) is a radiotracer that selectively binds to amyloid-β (Aβ) in senile plaques, which are a pathological hallmark of Alzheimer's disease (AD). This radiotracer has enabled a new era of pathology-targeted molecular imaging of neurodegenerative diseases. The recent development of 18 F-labelled radiotracers that are selective for Aβ, including 18 F-flutemetamol, 18 F-florbetapir, 18 F-florbetaben, and 18 F-NAV4694 (formerly 18 F-AZD4694), has also facilitated the application of Aβ-imaging for clinical use. [1] [2] [3] [4] Positron emission tomography (PET) using these Aβ-selective radiotracers clearly mirrors the extent of Aβ accumulation in the brain, 5, 6 thereby enabling an earlier diagnosis of prodromal AD. 7, 8 However, because neocortical Aβ pathology generally plateaus at an early stage of AD, 9 Aβ-imaging is less effective in delineating the progression of AD. 10 Paired helical filaments (PHF) of hyperphosphorylated tau protein are a major constituent of neurofibrillary tangles (NFT), the second major pathological hallmark of AD. 11 NFTs first appear in the transentorhinal region, spreading hierarchically to the neighboring limbic areas and distant association neocortices before finally reaching the primary cortices. 11 Because the distant propagation of tau pathology is preceded by an early and widespread dissemination of Aβ pathology in the neocortex, 9, 12 cortical tau burden is a better indicator of the clinical progression of AD. 13, 14 In addition, in contrast to the limited number of Aβ-related diseases, the existence of a wider clinical spectrum of tauopathies has necessitated the development of molecular imaging biomarkers for tau protein. 15 The development of the first tau-selective radiotracer, 18 F-THK523, in 2011 was another major breakthrough. 16 Although this PET radiotracer is currently no longer used for clinical research due to serious drawbacks that occurred in human studies, 17 it encouraged the development of better tau PET radiotracers that are now used in clinical research (Figure 1) .
Over recent years, clinical tau PET studies have primarily focused on the AD spectrum. Tau PET allows clear visualization of AD tau pathology with a high selectivity for PHF-tau 18, 19 and is now generally accepted as a useful imaging biomarker for assessing the pathological and clinical progression of AD. [20] [21] [22] In contrast to AD, postmortem autoradiography and a smaller number of in vivo tau PET studies in non-AD tauopathies have consistently reported weaker radiotracer binding to non-AD tau than to PHF-tau in AD. 18, 19, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In this review, we focus on recent progress in the knowledge of tau-selective tracers and clinical tau PET studies in degenerative parkinsonisms, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and multiple system atrophy (MSA). 
CHARACTERISTICS OF TAU-
F-THK-5351)
The first tau-selective radiotracer, 18 F-THK523, exhibited a 10-fold stronger binding affinity to pathological tau protein than to Aβ fibrils in vitro, selective binding to PHF-tau pathology in autoradiography studies with postmortem AD tissue, and stronger uptake in the brains of tau transgenic mice when compared to the wild-type or APP/PS1 transgenic mice. 16 In contrast to these promising results, subsequent in vivo human PET studies with 18 F-THK523 were quite disappointing due to high levels of white matter binding and low standardized uptake value ratio (SUVR) values, even in AD patients. 17 Regional differences in 18 F-THK523 binding in AD were only discernible with partial volume correction of the PET images. This regional difference was almost eliminated without the correction. Therefore, 18 F-THK523 has been deemed unsuitable for clinical tau PET imaging studies. 17 To overcome these issues, improvements to the F-THK-5351 PET study reported serious problems relating to monoamine oxidase-B (MAO-B) binding. 34 MAO-B is widely expressed in the brain, most prominently in the basal ganglia, followed by the insular cortex. 35 This topographical pattern was replicated in several in vivo PET studies. [36] [37] [38] In healthy controls and patients with mild cognitive impairment, AD, and PSP, one study conducted three 18 F-THK-5351 PET scans acquired before and after 10 mg of the MAO-B inhibitor, selegiline, was orally administered and again at 9-28 days after the selegiline treatment.
34 Surprisingly, a single oral dose of selegiline dramatically reduced 18 F-THK-5351 standardized uptake values by 37-52% across all regions, most prominently in the thalamus (52%) and basal ganglia (51%), and even in the cerebellar cortex (42%), which is generally used as a reference tissue. This suppressive effect was sustained until the third PET scan. 34 Therefore, the MAO-B binding characteristics of 18 F-THK-5351 may limit its applicability in tau imaging. 18 F-flortaucipir has exhibited a 25-fold greater binding affinity to PHF-tau than to Aβ, and very low white matter binding in several in vivo human PET studies. 39 As a result, 18 F-flortaucipir PET enables high contrasts between binding and background, which are helpful for detecting small increases in cortical binding. Unlike the similar radiotracer, 18 F-T808, which shows a high skull uptake in some subjects due to serious defluorination, 40 18 F-flortaucipir does not exhibit defluorination issues in human. 39, 41 Due to these positive findings, 18 F-flortaucipir has been most widely used for clinical tau imaging studies.
Autoradiography studies of postmortem tissues have consistently reported a stronger binding affinity of 18 F-flortaucipir to PHF-tau in AD, in contrast to its much weaker binding affinity to straight filament tau in non-AD tauopathies. 18, 19 Therefore, 18 Fflortaucipir is better for tau imaging studies in AD rather than in various other non-AD tauopathies.
However, there are two significant issues with 18 Fflortaucipir. First, unlike the other types of tau-selective radiotracers, which show stable SUVR values after a certain time point, 18 F-flortaucipir has unstable kinetics, causing the SUVR values to steadily increase even after 60 mins. 41 This characteristic can limit quantification attempts, especially in longitudinal studies, 42 although data acquired 80-100 mins post-injection can provide reliable SUVR values that correlate with the binding values determined by compartmental modeling. 43, 44 A second problem is the widely reported off-target binding. 18 F-flortaucipir also exhibits a high affinity for melanin-producing cells, including the substantia nigra, skin epithelium, retinal pigment epithelium, and melanomas. It, therefore, binds strongly to the substantia nigra, in which a high concentration of neuromelanin exists. 18,45 18 F-flortaucipir also strongly binds to the basal ganglia, even in healthy elderly individuals with an absence of tau pathology. 18, 45 One study showed a possible interaction with iron due to a correlation between age-related increases in basal ganglial iron content and 18 F-flortaucipir binding in the basal ganglia. 46 Nigral and basal ganglial offtarget binding is problematic for tau imaging, especially in parkinsonisms. The choroid plexus is another off-target binding site. Although one study found tangle-like structures that were immunoreactive to phosphorylated tau antibody in the epithelial cells in the choroid plexus, 47 the exact mechanism of this off-target binding remains unknown. Off-target binding in the choroid plexus also disturbs the precise quantitation of underlying hippocampal binding and can be an obstacle to early detection of hippocampal tau burden. 18 F-flortaucipir binds to MAO-A with a high affinity, 48 48, 49 In a small number of healthy elderly subjects and AD patients, 18 F-MK6240 exhibited fast washout, high binding to the cortical regions vulnerable to AD pathology, and a good correlation with the severity of cognitive impairment in AD. 50 Larger clinical PET studies are needed to better characterize the 18 F-MK6240 radiotracer. C-labelled tau-selective radiotracer that has an approximate 50-fold higher affinity for PHF-tau than that for Aβ. 51 An in vivo 11 C-PBB3 PET study also exhibited high tracer binding to the cortical regions of AD, similar to other types of tau-selective radiotracers. 51 More importantly, PBB3 also has a higher affinity for 4-repeat (4R) or 3R tau than 18 Fflortaucipir and is considered to be a tau PET tracer specific for a broader range of tau. 52 However, 11 C-PBB3 is rapidly metabolized in plasma, and radioactive metabolites that enter into the brain can contaminate PET signals. This problem makes 11 C-PBB3 unsuitable for quantification. 53, 54 In addition, high tracer retention in the venous sinus in all human subjects may contaminate PET signals around the venous sinus.
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LEWY BODY DISEASES
PD with normal cognition (PDNC), PD with mild cognitive impairment (PDMCI), PD with dementia (PDD), and DLB all share common clinical characteristics and neuropathology and are now considered to be part of the Lewy body diseases (LBD) spectrum. 55, 56 In addition to the well-known α-synuclein pathologies presenting as Lewy bodies and Lewy neurites, AD-type pathologies containing Aβ and PHF-tau are also found in LBD. 57, 58 Although the prevalence of Aβ-positivity seen in the 11 C-PIB PET studies of LBD, can be highly variable, 59 -64 a clearly increasing trend for the overall prevalence of Aβ-positivity within the LBD spectrum (5% in PDM-CI, 34% in PDD, and 68% in DLB) has been observed. 65 Therefore, a similar increasing trend of cortical binding in tau PET studies can be expected. All
18
F-flortaucipir PET studies in PD patients to date have consistently shown no increased binding in the basal ganglia or in the cerebral cortex. 25, [66] [67] [68] [69] PD patients exhibited approximately 13% lower 18 Fflortaucipir binding in the substantia nigra compared to controls, 25, 66, 67 due to off-target binding of 18 F-flortaucipir to neuromelanin pigment, which normally exists in the substantia nigra and is lost in PD (Figure 2) . 18, 19 Reduced 18 F-flortaucipir binding was more prominent in the lateral part of the substantia nigra than in the medial part. However, nigral 18 F-flortaucipir binding did not correlate with the motor severity of PD and did not reflect clinical asymmetry. 25, 66 DLB is positioned at the end of the LBD spectrum and can, therefore, be expected to exhibit the greatest cortical F-flortaucipir binding was increased in the inferior temporal and precuneus cortices in DLB and in the same area in PDCI, with a lower level of statistical significance. The binding in the inferior temporal and precuneus cortices correlated with the severity of cognitive impairment only in the composite group with DLB and PDCI. 68 The second 18 F-flortaucipir PET study involved 19 DLB and 19 AD patients. 70 Compared to the controls, the DLB patients showed greater binding in the posterior temporo-parietal and occipital cortices, in which 18 F-flortaucipir binding correlated with the global cortical 11 C-PIB binding. Interestingly, the medial temporal regions were relatively preserved in the DLB patients when compared to the AD patients, and for this reason, medial temporal 18 F-flortaucipir binding may be useful for differential diagnosis between DLB and AD. However, they found no correlation between the 18 F-flortaucipir binding and the severities of cognitive impairment and parkinsonian motor deficits. 70 A recent 18 F-flortaucipir PET study in a larger number of patients within the LBD spectrum (18 DLB, 22 PDCI, and 12 PDNC) showed a clearly increasing trend of cortical 18 F-flortaucipir binding within the LBD spectrum. 69 In this report, JMD icantly increased binding in the sensorimotor, primary visual, and parieto-temporal cortices, and the Aβ-positive PDCI group showed slightly increased binding in the middle and inferior temporal and parahippocampal cortices without surviving multiple comparisons. All Aβ-negative DLB, PDCI, and PDNC groups showed no increased binding in any of the cortical regions. In DLB, there was only a weak correlation between the severity of the cognitive impairment and binding in the prefrontal, sensorimotor, posterior cingulate, and occipital cortices. 69 In summary, the cortical tau burden observed in the 18 F-flortaucipir PET study increases within the LBD spectrum (Figure 3) . DLB patients exhibit the greatest tau burden, with distribution patterns distinct from AD. Cortical Aβ accumulation may play a greater role in pathological tau accumulation than α-synuclein does. The future development of radiotracers targeting α-synuclein will be helpful in investigating the interaction between the three pathological proteins, as well as for the differential diagnosis of LBD.
PROGRESSIVE SUPRANUCLEAR PALSY
Unlike the 3R and 4R tau isoform found in AD pathology, the 4R tau isoform is associated with PSP. 15 In PSP, central subcortical gray matter structures, such as the globus pallidus, subthalamic nucleus, and substantia nigra, are most vulnerable to the accumulation of pathological tau protein. In addition to these regions, the striatum, pontine nuclei, dentate nucleus, and cerebellar white matter are the second most vulnerable regions. Tau pathology is also frequently found in the frontal gray and white matter, predominantly in the posterior region, while tau accumulation in the parietal cortex occurs in severely affected patients. 71, 72 Although the pathological tau burden is most severe in the PSPRichardson's syndrome compared to the PSP-parkinsonism and PSP-pure akinesia with gait freezing types, all PSP subtypes commonly feature the prominent involvement of the central subcortical gray matter structures, and the clinical severity of PSP correlates with pathological tau burden. 72 The first attempt at in vivo PET imaging of pathological tau protein in PSP was performed with 2-(1-6-[ (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) F-fluoroethyl) (methyl) amino]-2-naphthylethylidene) malononitrile ( 18 F-FDDNP) PET, which non-selectively binds to tau, as well as to Aβ. 73 In this study, PSP patients exhibited increased 18 F-FDDNP binding primarily in the subcortical regions, including the striatum, thalamus, subthalamic nucleus, midbrain, and cerebellar white matter. However, PSP rating scale (PSPRS) scores correlated only with the binding in the frontal cortex. 73 Following the development of the tau-selective radiotracers, six 18 F-flortaucipir PET studies, including one case report and one 18 F-THK5351 PET study, were published in 2017. 25, 26, [30] [31] [32] 67, 74 All of these studies commonly found highly increased radiotracer binding in the globus pallidus and midbrain relative to controls. Five 18 F-flortaucipir PET studies additionally found increased binding in the striatum, 25, [30] [31] [32] 67 and four studies additionally observed increased binding in the cerebellar dentate nucleus. 25, 30, 32, 67 Only one study showed additionally increased 18 F-flortaucipir binding in the frontal cortex. 32 No correlation between disease severity measured by the PSPRS scores and radiotracer binding in any regions was found in any of the three studies, 25, 30, 67 while two studies found a weak correlation between the PSPRS scores and binding in the globus pallidus, 31 or that in the midbrain, thalamus, dentate nucleus, precentral cortex, supplementary motor area, middle frontal cortex, and inferior frontal cortex (Figures 2 and 3) . 32 It is very interesting to note that PSP patients can be discriminated by the high 18 F-flortaucipir binding in the globus pallidus with 93% sensitivity and 100% specificity. 25 A recent large study including 33 PSP patients and 26 PD patients replicated this finding (85% sensitivity and 92% specificity). 67 In contrast to the high in vivo 18 F-flortaucipir binding and a high amount of hyperphosphorylated tau in the globus pallidus and midbrain, autoradiography studies of postmortem tissues of PSP brains have shown weak binding of 18 F-flortaucipir, as with other types of non-AD tauopathies. 18, 19, 23, 30 It is still questionable whether high in vivo 18 F-flortaucipir binding in the globus pallidus and midbrain in PSP is true specific binding with a weak affinity or a result of unknown off-target binding.
Although there has been some variability seen in tau PET radiotracer binding, increased binding in the globus pallidus and midbrain, which are the most vulnerable to tau pathology in PSP, is considered a characteristic tau PET finding in PSP (Figures 2 and 3) . Tau PET may, therefore, be helpful for the differential diagnosis of PD and PSP.
CORTICOBASAL SYNDROME
CBS is a pathologically heterogeneous clinical syndrome characterized by parkinsonism, dystonia, apraxia, alien hand phenomenon, and myoclonus. [75] [76] [77] Corticobasal degeneration (CBD) is a pathological diagnosis accounting for almost half of CBS patients. [78] [79] [80] [81] [82] Considering the prevalence of other types of non-AD tauopathies in CBS, non-AD tau pathology can be found in over 70% of CBS patients. [78] [79] [80] [81] [82] Tau pathology featuring the 4R-isoform is found most prominently in the superior frontal and parietal cortices, as well as the perirolandic areas and their underlying white matter, and subcortical gray matter structures. 83, 84 Excluding three CBS patients who showed asymmetrically increased 18 F-flortaucipir binding in the parietotemporal cortex due to AD, 27 H-THK5351 binding in the frontal subcortical white matter, especially in the thread pathology. 86 Moreover, binding intensity in the autoradiography results correlated with the extent of tissue tau pathology. 86 In contrast, another autoradiography study with 18 Fflortaucipir showed very weak binding in a small part of the basal ganglia in which the greatest tau pathology existed, but antemortem in vivo 18 F-flor-JMD taucipir PET binding correlated with tau burden, as measured by immunohistochemical stains of postmortem tissue. 81 The first tau PET study of 18 F-THK5351 in five CBS patients revealed highly increased binding to the perirolandic cortical gray matter and underlying white matter, as well as in the basal ganglia, that was predominant in the side contralateral to the clinically more-affected side. 86 Likewise, two subsequent 18 F-flortaucipir PET studies supported this finding. 24, 27 Interestingly, these 18 F-flortaucipir PET studies commonly found a good correlation between the severity of parkinsonian motor deficit and 18 F-flortaucipir binding in the internal capsule 27 or the precentral gray matter and underlying white matter. 24 Tau PET distribution patterns in CBS patients are characterized by increased radiotracer binding predominantly in the motor cortex and the underlying white matter, as well as in the basal ganglia (Figure 3) . Although 18 F-flortaucipir binding is generally much weaker in CBS compared to AD, cortical or parkinsonian motor deficits may be attributable to tau burden in motor-related cortical gray matter and white matter, and basal ganglia.
MULTIPLE SYSTEM ATROPHY
Glial cytoplasmic inclusion (GCI) containing α-synuclein is a pathological hallmark of MSA, and can, therefore, be considered a synucleinopathy. 88 Although co-localization of tau pathology in GCIs has been reported in some patients with MSA, [89] [90] [91] [92] [93] tau pathology was found to be very rare in a postmortem study with a large number of MSA patients. 94 Therefore, it may be unlikely that there is increased 18 F-flortaucipir binding in the putamen, where GCI pathology is most prominent. However, one 18 F-flortaucipir PET study of four consecutive parkinsonian-type MSA patients clearly showed asymmetrically increased 18 F-flortaucipir binding in the atrophic posterior putamen, which was more prominent in the side ipsilateral to the greater putaminal atrophy, together with lower uptake of dopamine transporter PET contralateral to the clinically more affected side. 95 Considering the very low prevalence of tau pathology in MSA, it is unlikely that 18 F-flortaucipir bound specifically to tau protein co-localized in the atrophic putamen. Instead, the unexpected results could be attributable to unknown off-target binding.
In 18 F-flortaucipir PET, basal ganglial off-target binding is commonly observed even in healthy elderly individuals. 18, 41, 45 Interestingly, the topography of subcortical nuclei showing 18 F-flortaucipir binding is similar to that of iron in the brain, although an autoradiography study failed to find a spatial match within each region. 19 Greater iron content was demonstrated in the putamen of the MSA brains, [96] [97] [98] an effect that was replicated in quantitative MR imaging studies of brain iron. 99, 100 A recent iron-sensitive quantitative magnetic resonance imaging and 18 Fflortaucipir PET study showed a direct correlation between age-related increases in basal ganglial iron content and 18 F-flortaucipir binding. 46 Therefore, there may be an in vivo interaction between 18 F-flortaucipir and iron. Another possible mechanism for this unexpected binding can be explained by offtarget binding to the MAO-B expressed by reactive astrocytes, although 18 F-flortaucipir binding to MAO-B has not been proven. 101 However, regardless of the nature of the putaminal 18 F-flortaucipir binding in MSA, 18 F-flortaucipir PET may be useful for the differential diagnosis of parkinsonism due to its binding topography in the basal ganglia (Figure 3 ).
CONCLUSIONS
Although 18 F-flortaucipir is the most promising tau-selective radiotracer for imaging various tauopathies among the tau-selective radiotracers already validated by clinical PET studies, it has drawbacks: off-target binding, unstable kinetics, weak affinity to non-AD tau, and possible MAO binding. Nevertheless, 18 F-flortaucipir binds in distinct patterns in different degenerative parkinsonisms and is, therefore, a potential imaging biomarker for the differential diagnosis of parkinsonisms. Next generation tau-selective radiotracers without the problems that are common for the first generation radiotracers will be more helpful for the visualization of tau pathology in degenerative parkinsonisms, as well as in AD. Furthermore, tau PET will be a good imaging biomarker for monitoring the response to pathology-targeted immunotherapy in these tauopathies.
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